Rite Aid Corporation (NYSE:RAD) on Thursday said sales at stores open at least a year grew 4.8% for the four weeks ended Jan. 24, with pharmacy-sales growth outpacing growth in the front end. For the four-week period, Rite Aid said total drugstore sales rose 4.3% to $1.94 billion. The pharmacy business reported a 5.7% rise in same-store sales, which included negative impact of 1.14 percentage points stemming from new generic drugs. The prescription count rose 3.5%. On Friday shares of Rite Aid Corporation (NYSE:RAD) closed at $6.98. Company’s sales growth for last 5 years was -0.60% and EPS growth for next 5 years is recorded as 39.71%.
Alcoa (NYSE:AA) officially opened its expanded wheels manufacturing plant in Hungary. The larger facility doubles Alcoa’s capacity to produce its Dura-Bright® EVO surface-treated wheels compared to 2014 production levels. The expansion will enable Alcoa to meet growing European demand for its lightweight, durable, low-maintenance aluminum truck wheels. Alcoa Inc. (NYSE:AA) in last trading activity fell -2.07% to close at $15.65. Company weekly performance is -0.70% while its quarterly performance stands at -3.63%. Alcoa Inc. (NYSE:AA) is -11.83% away from its 52 week high.
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results. On last trading day Medgenics, Inc. (NYSEMKT:MDGN) advanced 1.10% to close at $8.30. Its volatility for the week is 6.28% while volatility for the month is 8.98%. MDGN’s EPS growth for past 5 years was 10.00%. Medgenics, Inc. (NYSEMKT:MDGN) monthly performance is 66.33%.
Digital Realty Trust Inc. (NYSE:DLR), announced an organizational change designed to better leverage and develop the company’s management resources. Jim Smith, Digital Realty’s Chief Technology Officer, and David Schirmacher, Senior Vice President of Operations, will switch roles effective March 1, 2015. Digital Realty Trust Inc. (NYSE:DLR) has 0.26% insider ownership. In last trading activity company’s stock closed at $72.94.
Response Genetics, Inc (NASDAQ:RGDX) announced that the company presented two abstracts at American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, during January 15 to 17, 2015. One presentation, entitled “Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients” demonstrates the clinical utility of Response Genetics’ proprietary ResponseDX® KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled “EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)” provides further clinical evidence for the company’s patented ERCC1 mRNA expression technology in predicting response to chemotherapy. On last trading day Response Genetics, Inc (NASDAQ:RGDX) advanced 2.54% to close at $0.43. Its volatility for the week is 18.39% while volatility for the month is 16.08%. RGDX’s sales growth for past 5 years was 22.80% and its EPS growth for past 5 years was 20.30%. Response Genetics, Inc (NASDAQ:RGDX) monthly performance is 30.79%.